https://mb.cision.com/Public/18595/3636902/999776931e930491_800x800ar.png
** FINTEPLA^=C2=AE=E2=96=BC (fenfluramine) Approved in Japan for the Treatm=
ent of Seizures Associated with Dravet Syndrome
------------------------------------------------------------
=C2=B7 Approval supported by clinical trial data that showed when added to =
existing treatment regimens, fenfluramine significantly reduced monthly con=
vulsive seizure frequency compared to placebo^1
=C2=B7 Approval highlights UCB's commitment to expanding global access to f=
enfluramine; an estimated 3,000 =E2=80=93 6,000 patients live with Dravet s=
yndrome in Japan^2
Brussels (Belgium), 27 September 2022 =E2=80=93 7.00 (CET) =E2=80=93 UCB, a=
global biopharmaceutical company, today announced that FINTEPLA^=C2=AE=E2=
=96=BC (fenfluramine) oral solution has been approved by the Japanese Minis=
try of Health, Labour and Welfare (MHLW) for the treatment of seizures asso=
ciated with Dravet syndrome as an add-on therapy to other anti-epileptic me=
dicines for patients 2 years of age and older.^3 FINTEPLA^=C2=AE will be av=
ailable at all Japanese hospitals and pharmacies.
Fenfluramine will be marketed by Nippon Shinyaku Co., Ltd. based on the exc=
lusive sales agreement signed in 2019 between Zogenix Inc., (acquired by UC=
B in 2022) and Nippon Shinyaku Co., Ltd. UCB is now the Marketing Authoriza=
tion holder.
=E2=80=9CThis approval in Japan delivers on our commitment towards expandin=
g access to new treatment options to address unmet needs of those living wi=
th refractory epilepsy across the globe,=E2=80=9D said Charl van Zyl, Execu=
tive Vice President, Neurology Solutions, UCB. =E2=80=9CWe would like to th=
ank our Japanese patients and families for participating in the clinical tr=
ial and making this significant milestone happen so that more people with D=
ravet syndrome can help achieve their treatment goals.=E2=80=9D
The MHLW approval was based a clinical trial program including data from a =
multi-national randomized, double-blind, placebo-controlled study of 143 ch=
ildren and young adults (2-18 years) with Dravet syndrome [that included tr=
ial participants from Japan], whose seizures were not adequately controlled=
with existing anti-epileptic medications. The study showed that when added=
to existing treatment regimens, those treated with 0.7 mg/kg day fenfluram=
ine experienced a greater reduction (64.8%) in mean monthly convulsive seiz=
ures compared to placebo (P <.0001). The median age of patients in the stud=
y was 9 years (range, 2=E2=80=9318) and the average baseline convulsive sei=
zure frequency across the study groups was approximately 63 seizures per mo=
nth. Following a 6-week baseline observation period, patients were randomiz=
ed to 1 of 3 treatment groups: 0.7 mg/kg per day (n =3D 49), 0.2 mg/kg per =
day (n =3D 46), or placebo (n =3D 48), in which fenfluramine or placebo was=
added to each patient=E2=80=99s current treatment regimen of anti-epilepti=
c drugs. Patients were titrated to their target dose of fenfluramine over 2=
weeks and then remained at that fixed dose for 12 weeks (26-mg maximum dai=
ly dose).^1
The incidence of treatment-emergent adverse events was higher in the treatm=
ent groups as compared to the placebo group, with 91.7% (n=3D44) of patient=
s in the 0.7 mg/kg/day group and 91.3% (n=3D42) of patients in the 0.2 mg/k=
g/day group experiencing at least one treatment-emergent adverse event comp=
ared to 83.3% (n=3D40) of patients in the placebo group. The incidence of s=
erious adverse events was similar in all three groups with 6.3% (n=3D3) of =
patients in the 0.7 mg/kg/day group and 6.5% (n=3D3) of patients in the 0.2=
mg/kg/day group experiencing at least one treatment-emergent serious adver=
se event compared to 4.2% (n=3D2) of patients in the placebo group, includi=
ng one placebo patient who died due to SUDEP (sudden unexpected death in ep=
ilepsy). Prospective cardiac safety monitoring throughout the study showed =
that no study patients developed valvular heart disease or pulmonary arteri=
al hypertension.^1
As a condition of regulatory approval in Japan, UCB is required to undertak=
e various post-marketing surveillance programs.
About Dravet Syndrome=C2=A0
Dravet syndrome is a rare, devastating and life-long form of developmental =
and epileptic encephalopathy that generally begins in infancy and is marked=
by frequent, treatment-resistant seizures, significant developmental, moto=
r, and behavioral impairments, and an increased risk of mortality and sudde=
n unexpected death in epilepsy (SUDEP). Most patients follow a course of de=
velopmental delay with cognitive, motor and behavioral deficits that persis=
t into adulthood. Dravet syndrome severely impacts quality of life for pati=
ents, families, and caregivers due to the high physical, emotional, caregiv=
ing, and financial burden associated with the disease.^4,5,6
About fenfluramine C-IV
Fenfluramine oral solution is a prescription medication used to treat seizu=
res associated with Dravet syndrome in patients two years of age and older.=
Fenfluramine and the metabolite, norfenfluramine, increase extracellular l=
evels of serotonin through interaction with serotonin transporter proteins,=
and exhibit agonist activity at serotonin 5HT-2 receptors. ^7,8
Key Safety Information about FINTEPLA^=C2=AE=E2=96=BC in EU^7
Aortic or mitral valvular heart disease and pulmonary arterial hypertension
Because of reported cases of valvular heart disease that may have been caus=
ed by fenfluramine at higher doses used to treat adult obesity, cardiac mon=
itoring must be performed using echocardiography. In the controlled clinica=
l studies of fenfluramine for the treatment of Dravet syndrome, no valvular=
heart disease was observed.
Prior to starting treatment, patients must undergo an echocardiogram to est=
ablish a baseline prior to initiating treatment and exclude any pre-existin=
g valvular heart disease or pulmonary hypertension.
Echocardiogram monitoring should be conducted every 6 months for the first =
2 years and annually thereafter. If an echocardiogram indicates pathologica=
l valvular changes, a follow-up echocardiogram should be considered at an e=
arlier timeframe to evaluate whether the abnormality is persistent. If path=
ological abnormalities on the echocardiogram are observed, it is recommende=
d to evaluate the benefit versus risk of continuing fenfluramine treatment =
with the prescriber, caregiver, and cardiologist.
If treatment is stopped because of aortic or mitral valvular heart disease,=
appropriate monitoring and follow-up should be provided in accordance with=
local guidelines for the treatment of aortic or mitral valvular heart dise=
ase.
With past use in higher doses to treat adult obesity, fenfluramine was repo=
rted to be associated with pulmonary arterial hypertension. Pulmonary arter=
ial hypertension was not observed in the clinical programme, but because of=
the low incidence of this disease, the clinical trial experience with fenf=
luramine is inadequate to determine if fenfluramine increases the risk for =
pulmonary arterial hypertension in patients with Dravet syndrome.
If echocardiogram findings are suggestive of pulmonary arterial hypertensio=
n, a repeat echocardiogram should be performed as soon as possible and with=
in 3 months to confirm these findings. If the echocardiogram finding is con=
firmed suggestive of an increased probability of pulmonary arterial hyperte=
nsion defined as =E2=80=9Cintermediate probability=E2=80=9D by the 2015 Eur=
opean Society of Cardiology (ESC) and the European Respiratory Society (ERS=
) Guidelines, it should lead to a benefit-risk evaluation of continuation o=
f Fintepla by the prescriber, carer, and cardiologist. If the echocardiogra=
m finding, after confirmation, suggests of a high probability of pulmonary =
arterial hypertension, as defined by the 2015 ESC and ERS Guidelines, it is=
recommended fenfluramine treatment should be stopped.
Decreased appetite and weight loss
Fenfluramine can cause decreased appetite and weight loss. An additive effe=
ct on decreased appetite can occur when fenfluramine is combined with other=
anti-epileptic medicines, for example stiripentol. The decrease in weight =
appears to be dose related. Most subjects resumed weight gain over time whi=
le continuing treatment. The patient's weight should be monitored. A benefi=
t risk evaluation should be undertaken prior to commencing treatment with f=
enfluramine in patients with a history of anorexia nervosa or bulimia nervo=
sa.
Fintepla controlled access programme
A controlled access programme has been created to 1) prevent off-label use =
in weight management in obese patients and 2) confirm that prescribing phys=
icians have been informed of the need for periodic cardiac monitoring in pa=
tients taking Fintepla.=C2=A0
Somnolence
Fenfluramine can cause somnolence.
Other central nervous system depressants, including alcohol, could potentia=
te the somnolence effect of fenfluramine.
Suicidal behaviour and ideation=C2=A0
Suicidal behaviour and ideation have been reported in patients treated with=
anti-epileptic medicines in several indications. A meta-analysis of random=
ised placebo-controlled trials with anti-epileptic medicines that did not i=
nclude fenfluramine has shown a small increased risk of suicidal behaviour =
and ideation. The mechanism of this risk is not known, and the available da=
ta do not exclude the possibility of an increased risk for fenfluramine. Pa=
tients and caregivers of patients should be advised to seek medical advice =
should any signs of suicidal behaviour and ideation emerge.
Serotonin syndrome
As with other serotonergic agents, serotonin syndrome, a potentially life-t=
hreatening condition, may occur with fenfluramine treatment, particularly w=
ith concomitant use of other serotonergic agents (including SSRIs, SNRIs, t=
ricyclic antidepressants, or triptans); with agents that impair metabolism =
of serotonin such as MAOIs; or with antipsychotics that may affect the sero=
tonergic neurotransmitter systems.
Serotonin syndrome symptoms may include mental status changes (eg, agitatio=
n, hallucinations, coma), autonomic instability (eg, tachycardia, labile bl=
ood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, =
incoordination), and/or gastrointestinal symptoms (eg, nausea, vomiting, di=
arrhoea).
If concomitant treatment with fenfluramine and other serotonergic agents th=
at may affect the serotonergic systems is clinically warranted, careful obs=
ervation of the patient is advised, particularly during treatment initiatio=
n and dose increases.
Increased seizure frequency
As with other anti-epileptic medicines, a clinically relevant increase in s=
eizure frequency may occur during treatment with fenfluramine, which may re=
quire adjustment in the dose of fenfluramine and/or concomitant anti-epilep=
tic medicines, or discontinuation of fenfluramine, should the benefit-risk =
be negative.=C2=A0
Cyproheptadine=C2=A0
Cyproheptadine is a potent serotonin receptor antagonist and may therefore =
decrease the efficacy of fenfluramine. If cyproheptadine is added to treatm=
ent with fenfluramine, patients should be monitored for worsening of seizur=
es. If fenfluramine treatment is initiated in a patient taking cyproheptadi=
ne, fenfluramine=E2=80=99s efficacy may be reduced.
Glaucoma
Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma=
. Discontinue therapy in patients with acute decreases in visual acuity. Co=
nsider discontinuation if there is ocular pain and another cause cannot be =
determined.
Strong CYP1A2 or CYP2B6 inducers
Co-administration with strong CYP1A2 inducers or CYP2B6 inducers may decrea=
se fenfluramine plasma concentrations. An increase in fenfluramine dosage s=
hould be considered when co-administered with a strong CYP1A2 or CYP2B6 ind=
ucer; the maximum daily dose should not be exceeded.
Excipients
This medicinal product contains sodium ethyl para-hydroxybenzoate (E 215) a=
nd sodium methyl para hydroxybenzoate (E 219) which may cause allergic reac=
tions (possibly delayed). It also contains sulfur dioxide (E 220) which may=
rarely cause severe hypersensitivity reactions and bronchospasm.
Patients with rare glucose-galactose malabsorption should not take this med=
icinal product.
This medicinal product contains less than 1 mmol sodium (23 mg) per the max=
imum daily dose of 12 mL, that is to say essentially =E2=80=98sodium-free=
=E2=80=99.
This medicinal product contains glucose which may be harmful to the teeth.
For further safety information and full prescribing information visit: Fint=
epla, INN-fenfluramine (europa.eu) (https://www.ema.europa.eu/en/documents/=
product-information/fintepla-epar-product-information_en.pdf)
Key Safety Information about FINTEPLA^=C2=AE=E2=96=BC in Japan^3 =C2=A0
The administration of fenfluramine, the active ingredient of FINTEPLA, has =
been reported to be associated with valvular heart disease and pulmonary ar=
terial hypertension. The following monitoring should be performed in collab=
oration with a cardiologist.
Before starting FINTEPLA treatment, the presence or absence of cardiac dise=
ases should be confirmed by echocardiography, etc.
During the FINTEPLA treatment period, echocardiography and also adequate ob=
servation (e.g., physical findings such as auscultation, chest X-ray, elect=
rocardiogram, etc.) should be performed periodically.=C2=A0
If echocardiography reveals any valvular abnormalities, additional echocard=
iography should be performed to make sure the abnormality does not persist.=
If echocardiography reveals findings indicative of valvular heart disease =
or pulmonary arterial hypertension, a decision on whether FINTEPLA can be a=
dministered should be reached based on a careful consideration of the risks=
and benefits for initiating or continuing treatment. =C2=A0
FINTEPLA can cause decreased appetite. Patients and their caregivers should=
be thoroughly informed in advance and instructed to visit their physicians=
if necessary. Since weight loss may occur, patients should be carefully mo=
nitored during treatment with this product, including periodic weigh-ins, a=
nd if weight loss is observed, a dosage reduction should be considered.
Since FINTEPLA may cause drowsiness and impaired attention, concentration, =
and reflex-motor skills, advise patients and caregiver should be cautioned =
that patients taking FINTEPLA should not drive a car or operate other hazar=
dous machineries.
Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma=
. Consider discontinuing treatment with FINTEPLA in patients with acute dec=
reases in visual acuity or ocular pain.
When discontinuing FINTEPLA, the dose should be reduced gradually to minimi=
ze the risk of increased seizure frequency and status epilepticus.
For further safety information and full Japanese prescribing information vi=
sit: =E3=83=95=E3=82=A3=E3=83=B3=E3=83=86=E3=83=97=E3=83=A9=E5=86=85=E7=94=
=A8=E6=B6=B22.2mg/mL (pmda.go.jp) (https://www.info.pmda.go.jp/go/pack/1139=
0B0S1026_1_01/?view=3Dframe&style=3DXML&lang=3Dja)
^=E2=96=BCThis medicinal product is subject to additional monitoring. This =
will allow quick identification of new safety information. Healthcare profe=
ssionals are asked to report any suspected adverse reactions.
For further information, contact UCB:=C2=A0
Media/Corporate Communications=C2=A0
Laurent Schots
T +32 2 559 9264 | laurent.schots@ucb.com
Nick Francis
T +44 7769 307745 | nick.francis@ucb.com
Investor Relations
Antje Witte,
Investor Relations, UCB
T +32.2.559.9414
antje.witte@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 600 people in=
approximately 40 countries, the company generated revenue of =E2=82=AC5.3 =
billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow u=
s on Twitter: @UCB_news
Forward looking statements=C2=A0
This press release contains forward-looking statements including, without l=
imitation, statements containing the words "believes", "anticipates", "expe=
cts", "intends", "plans", "seeks", "estimates", "may", "will", "continue" a=
nd similar expressions. These forward-looking statements are based on curre=
nt plans, estimates and beliefs of management. All statements, other than s=
tatements of historical facts, are statements that could be deemed forward-=
looking statements, including but not limited to, the ability of UCB to suc=
cessfully integrate the operations of Zogenix as planned or at all, estimat=
es of revenues, operating margins, capital expenditures, cash, other financ=
ial information, expected legal, arbitration, political, regulatory or clin=
ical results or practices and other such estimates and results. By their na=
ture, such forward-looking statements are not guarantees of future performa=
nce and are subject to known and unknown risks, uncertainties and assumptio=
ns which might cause the actual results, financial condition, performance o=
r achievements of UCB, or industry results, to differ materially from those=
that may be expressed or implied by such forward-looking statements contai=
ned in this press release. Important factors that could result in such diff=
erences include: the global spread and impact of COVID-19, changes in gener=
al economic, business and competitive conditions, the inability to obtain n=
ecessary regulatory approvals or to obtain them on acceptable terms or with=
in expected timing, costs associated with research and development, changes=
in the prospects for products in the pipeline or under development by UCB,=
effects of future judicial decisions or governmental investigations, safet=
y, quality, data integrity or manufacturing issues; potential or actual dat=
a security and data privacy breaches, or disruptions of our information tec=
hnology systems, product liability claims, challenges to patent protection =
for products or product candidates, competition from other products includi=
ng biosimilars, changes in laws or regulations, exchange rate fluctuations,=
changes or uncertainties in tax laws or the administration of such laws, a=
nd hiring and retention of its employees. There is no guarantee that new pr=
oduct candidates will be discovered or identified in the pipeline, or that =
new indications for existing products will be developed and approved. Movem=
ent from concept to commercial product is uncertain; preclinical results do=
not guarantee safety and efficacy of product candidates in humans. So far,=
the complexity of the human body cannot be reproduced in computer models, =
cell culture systems or animal models. The length of the timing to complete=
clinical trials and to get regulatory approval for product marketing has v=
aried in the past and UCB expects similar unpredictability going forward. P=
roducts or potential products which are the subject of partnerships, joint =
ventures or licensing collaborations may be subject to disputes between the=
partners or may prove to be not as safe, effective or commercially success=
ful as UCB may have believed at the start of such partnership. UCB' efforts=
to acquire other products or companies and to integrate the operations of =
such acquired companies may not be as successful as UCB may have believed a=
t the moment of acquisition. Also, UCB or others could discover safety, sid=
e effects or manufacturing problems with its products and/or devices after =
they are marketed. The discovery of significant problems with a product sim=
ilar to one of UCB's products that implicate an entire class of products ma=
y have a material adverse effect on sales of the entire class of affected p=
roducts. Moreover, sales may be impacted by international and domestic tren=
ds toward managed care and health care cost containment, including pricing =
pressure, political and public scrutiny, customer and prescriber patterns o=
r practices, and the reimbursement policies imposed by third-party payers a=
s well as legislation affecting biopharmaceutical pricing and reimbursement=
activities and outcomes. Finally, a breakdown, cyberattack or information =
security breach could compromise the confidentiality, integrity and availab=
ility of UCB's data and systems.
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and expressly disclaims any duty to=
update any information contained in this press release, either to confirm =
the actual results or to report or reflect any change in its forward-lookin=
g statements with regard thereto or any change in events, conditions or cir=
cumstances on which any such statement is based, unless such statement is r=
equired pursuant to applicable laws and regulations.
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
FINTEPLA^=C2=AE and Zogenix, Inc. are registered trademarks of the UCB Grou=
p of Companies.
References
1. UCB Data on File. Sullivan, J. AES. 2020. Poster 853.
2. Yamada M, Suzuki K, Matsui D, Inoue Y, Ohtsuka Y. Long-term safety and e=
ffectiveness of stiripentol in patients with Dravet syndrome: Interim repor=
t of a post-marketing surveillance study in Japan. Epilepsy Res. 2021;170:1=
06535.
3. Fintepla Japan PI. September 2022. =E3=83=95=E3=82=A3=E3=83=B3=E3=83=86=
=E3=83=97=E3=83=A9=E5=86=85=E7=94=A8=E6=B6=B22.2mg/mL (pmda.go.jp) (https:/=
/www.info.pmda.go.jp/go/pack/11390B0S1026_1_01/?view=3Dframe&style=3DXML&la=
ng=3Dja) . Accessed September 2022
4. Dravet C. The Core Dravet Syndrome Phenotype. Epilepsia. 2011 Apr;52 Sup=
pl 2:3-9.
5. Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011 Apr;53 Sup=
pl 2:1-6.
6. Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet Syndrome in t=
he US Population. Pediatrics. 2015 Nov;136(5):e1310-1315.
7. Fintepla EMEA SmPC.https://www.ema.europa.eu/en/documents/product-inform=
ation/fintepla-epar-product-information_en.pdf. Accessed September 2022
8. Fintepla=C2=AE US PI. https://www.accessdata.fda.gov/drugsatfda_docs/lab=
el/2020/212102s000lbl.pdf. Accessed September 2022
GenericFile
Japan approval of FINTEPLA- Press Release Approved ENG (https://mb.cision.c=
om/Public/18595/3636902/bc76b4f66c7a4a3f.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x117072x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium